Conflicting cerebrospinal fluid biomarkers and progression to dementia due to Alzheimer’s disease

[1]  N. Laskaris,et al.  Mapping CSF biomarker profiles onto NIA–AA guidelines for Alzheimer’s disease , 2016, European Archives of Psychiatry and Clinical Neuroscience.

[2]  S. Duchesne,et al.  Predicting Alzheimer's disease development: a comparison of cognitive criteria and associated neuroimaging biomarkers , 2015, Alzheimer's Research & Therapy.

[3]  Giovanni B. Frisoni,et al.  Prediction of AD dementia by biomarkers following the NIA-AA and IWG diagnostic criteria in MCI patients from three European memory clinics , 2015, Alzheimer's & Dementia.

[4]  Claire Paquet,et al.  Cerebrospinal fluid amyloid-β 42/40 ratio in clinical setting of memory centers: a multicentric study , 2015, Alzheimer's Research & Therapy.

[5]  P. Scheltens,et al.  Diagnostic impact of CSF biomarkers for Alzheimer's disease in a tertiary memory clinic , 2015, Alzheimer's & Dementia.

[6]  W. M. van der Flier,et al.  Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. , 2015, Brain : a journal of neurology.

[7]  K. Blennow,et al.  The cerebrospinal fluid “Alzheimer profile”: Easily said, but what does it mean? , 2014, Alzheimer's & Dementia.

[8]  F. Pasquier,et al.  Impact of harmonization of collection tubes on Alzheimer's disease diagnosis , 2014, Alzheimer's & Dementia.

[9]  Nick C Fox,et al.  A data-driven model of biomarker changes in sporadic Alzheimer's disease , 2014, Alzheimer's & Dementia.

[10]  Philip Scheltens,et al.  Variability of CSF Alzheimer’s Disease Biomarkers: Implications for Clinical Practice , 2014, PloS one.

[11]  Nick C Fox,et al.  Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria , 2014, The Lancet Neurology.

[12]  N. Laskaris,et al.  Limited agreement between biomarkers of neuronal injury at different stages of Alzheimer's disease , 2014, Alzheimer's & Dementia.

[13]  Charless C. Fowlkes,et al.  Alzheimer’s Disease Neuroimaging Initiative , 2005 .

[14]  C. Jack,et al.  Biomarker Modeling of Alzheimer’s Disease , 2013, Neuron.

[15]  W. Jagust,et al.  Diagnostic accuracy of markers for prodromal Alzheimer's disease in independent clinical series , 2013, Alzheimer's & Dementia.

[16]  L. Lannfelt,et al.  High Tau Levels in Cerebrospinal Fluid Predict Rapid Decline and Increased Dementia Mortality in Alzheimer's Disease , 2013, Dementia and Geriatric Cognitive Disorders.

[17]  C. Jack,et al.  Mild cognitive impairment due to Alzheimer disease in the community , 2013, Annals of neurology.

[18]  Leslie M. Shaw,et al.  Longitudinal change in CSF Tau and Aβ biomarkers for up to 48 months in ADNI , 2013, Acta Neuropathologica.

[19]  W. Kirsch,et al.  From development to dysfunction: Microglia and the complement cascade in CNS homeostasis , 2013, Ageing Research Reviews.

[20]  A. Kurz,et al.  The National Institute on Aging-Alzheimer’s Association research criteria for mild cognitive impairment due to Alzheimer’s disease: predicting the outcome , 2013, European Archives of Psychiatry and Clinical Neuroscience.

[21]  C. Rowe,et al.  Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study , 2013, The Lancet Neurology.

[22]  W. M. van der Flier,et al.  Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI , 2013, Neurology.

[23]  Stephen F. Carter,et al.  Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease , 2013, Neurology.

[24]  C. Jack,et al.  Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers , 2013, The Lancet Neurology.

[25]  Daniel Rueckert,et al.  Injury markers predict time to dementia in subjects with MCI and amyloid pathology , 2012, Neurology.

[26]  J. Molinuevo,et al.  Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. , 2012, Biomarkers in medicine.

[27]  P. Dunkel,et al.  Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis , 2012, Expert opinion on investigational drugs.

[28]  Philip S. Insel,et al.  Development and assessment of a composite score for memory in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) , 2012, Brain Imaging and Behavior.

[29]  B. Barres,et al.  The complement system: an unexpected role in synaptic pruning during development and disease. , 2012, Annual review of neuroscience.

[30]  C. Jack,et al.  An operational approach to National Institute on Aging–Alzheimer's Association criteria for preclinical Alzheimer disease , 2012, Annals of neurology.

[31]  Philip S. Insel,et al.  A composite score for executive functioning, validated in Alzheimer’s Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment , 2012, Brain Imaging and Behavior.

[32]  K. Blennow,et al.  Cerebrospinal fluid levels of complement proteins C3, C4 and CR1 in Alzheimer’s disease , 2012, Journal of Neural Transmission.

[33]  W. Kukull,et al.  Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010 , 2012, Journal of neuropathology and experimental neurology.

[34]  Mark E. Schmidt,et al.  The Alzheimer’s Disease Neuroimaging Initiative: A review of papers published since its inception , 2012, Alzheimer's & Dementia.

[35]  H. Hampel,et al.  Stage-dependent agreement between cerebrospinal fluid proteins and FDG-PET findings in Alzheimer's disease. , 2012, Current Alzheimer research.

[36]  W. M. van der Flier,et al.  Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort , 2012, Neurology.

[37]  L. McEvoy,et al.  Predicting MCI outcome with clinically available MRI and CSF biomarkers , 2011, Neurology.

[38]  T. Goldberg,et al.  Utility of combinations of biomarkers, cognitive markers, and risk factors to predict conversion from mild cognitive impairment to Alzheimer disease in patients in the Alzheimer's disease neuroimaging initiative. , 2011, Archives of general psychiatry.

[39]  K. Yaffe,et al.  The projected effect of risk factor reduction on Alzheimer's disease prevalence , 2011, The Lancet Neurology.

[40]  R. Veerhuis,et al.  Complement in the brain. , 2011, Molecular immunology.

[41]  G. McKhann.  Changing concepts of Alzheimer disease. , 2011, JAMA.

[42]  Nick C Fox,et al.  The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[43]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[44]  M. Albert,et al.  Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[45]  Aneeka M Hancock,et al.  Complement 3 and factor h in human cerebrospinal fluid in Parkinson's disease, Alzheimer's disease, and multiple-system atrophy. , 2011, The American journal of pathology.

[46]  Xavier Robin,et al.  pROC: an open-source package for R and S+ to analyze and compare ROC curves , 2011, BMC Bioinformatics.

[47]  Jason J. Corneveaux,et al.  CR1 is associated with amyloid plaque burden and age‐related cognitive decline , 2011, Annals of neurology.

[48]  M. Ferretti,et al.  Does a pro-inflammatory process precede Alzheimer's disease and mild cognitive impairment? , 2011, Current Alzheimer research.

[49]  Robert A. Dean,et al.  Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI , 2011, Acta Neuropathologica.

[50]  William N. Venables,et al.  Modern Applied Statistics with S , 2010 .

[51]  S. Potkin,et al.  Genome-wide association study of CSF biomarkers Aβ1-42, t-tau, and p-tau181p in the ADNI cohort , 2010, Neurology.

[52]  Cindee M. Madison,et al.  Comparing predictors of conversion and decline in mild cognitive impairment , 2010, Neurology.

[53]  W. M. van der Flier,et al.  Diagnostic Impact of CSF Biomarkers in a Local Hospital Memory Clinic , 2010, Dementia and Geriatric Cognitive Disorders.

[54]  Jason H. Moore,et al.  Alzheimer's Disease Neuroimaging Initiative biomarkers as quantitative phenotypes: Genetics core aims, progress, and plans , 2010, Alzheimer's & Dementia.

[55]  Joseph V. Hajnal,et al.  A robust method to estimate the intracranial volume across MRI field strengths (1.5T and 3T) , 2010, NeuroImage.

[56]  C. Jack,et al.  Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects , 2010, Alzheimer's & Dementia.

[57]  K. Blennow,et al.  Cerebrospinal fluid total tau as a marker of Alzheimer's disease intensity , 2010, International journal of geriatric psychiatry.

[58]  Murray Grossman,et al.  Novel CSF biomarkers for Alzheimer’s disease and mild cognitive impairment , 2010, Acta Neuropathologica.

[59]  Aneeka M Hancock,et al.  DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. , 2010, Brain : a journal of neurology.

[60]  Nick C Fox,et al.  The clinical use of structural MRI in Alzheimer disease , 2010, Nature Reviews Neurology.

[61]  J. Lambert,et al.  Association study of the CFH Y402H polymorphism with Alzheimer's disease , 2010, Neurobiology of Aging.

[62]  C. Jack,et al.  Alzheimer's Disease Neuroimaging Initiative (ADNI) , 2010, Neurology.

[63]  W. M. van der Flier,et al.  CSF biomarkers predict rate of cognitive decline in Alzheimer disease , 2009, Neurology.

[64]  M. Weiner,et al.  Relationships between biomarkers in aging and dementia , 2009, Neurology.

[65]  L. Kiemeney,et al.  Corrigendum: Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer , 2009, Nature Genetics.

[66]  Nick C Fox,et al.  Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease, and shows evidence for additional susceptibility genes , 2009, Nature Genetics.

[67]  P. Bosco,et al.  Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease , 2009, Nature Genetics.

[68]  C. Jack,et al.  MRI and CSF biomarkers in normal, MCI, and AD subjects , 2009, Neurology.

[69]  W. M. van der Flier,et al.  CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. , 2009, JAMA.

[70]  R. Petersen,et al.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects , 2009, Annals of neurology.

[71]  H. Lehfeld,et al.  [Comparison of patient therapy adherence of two structural different memory clinics]. , 2009, Fortschritte der Neurologie-Psychiatrie.

[72]  A. Blom,et al.  Complement activation and inhibition: a delicate balance. , 2009, Trends in immunology.

[73]  E. Sinforiani,et al.  Cerebrospinal fluid levels of tau phosphorylated at threonine 181 in patients with Alzheimer’s disease and vascular dementia , 2008, Neurological Sciences.

[74]  Max Kuhn,et al.  Building Predictive Models in R Using the caret Package , 2008 .

[75]  K. Blennow,et al.  Association of complement factor H Y402H gene polymorphism with Alzheimer's disease , 2008, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[76]  R. Bartha,et al.  Ventricular enlargement as a possible measure of Alzheimer's disease progression validated using the Alzheimer's disease neuroimaging initiative database. , 2008, Brain : a journal of neurology.

[77]  Jau-Shyong Hong,et al.  Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression. , 2008, Trends in immunology.

[78]  C. Lemere,et al.  Complement C3 Deficiency Leads to Accelerated Amyloid β Plaque Deposition and Neurodegeneration and Modulation of the Microglia/Macrophage Phenotype in Amyloid Precursor Protein Transgenic Mice , 2008, The Journal of Neuroscience.

[79]  Nick C Fox,et al.  The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods , 2008, Journal of magnetic resonance imaging : JMRI.

[80]  P. Mecocci,et al.  Mild Cognitive Impairment: Epidemiology and Dementia Risk in an Elderly Italian Population , 2008, Journal of the American Geriatrics Society.

[81]  M. Trabucchi,et al.  Conversion of amnestic Mild Cognitive Impairment to dementia of Alzheimer type is independent to memory deterioration , 2007, International journal of geriatric psychiatry.

[82]  A. Kurz,et al.  DO ALL PATIENTS WITH MILD COGNITIVE IMPAIRMENT PROGRESS TO DEMENTIA? , 2006, Journal of the American Geriatrics Society.

[83]  A. Kurz,et al.  Progression to Dementia in Clinical Subtypes of Mild Cognitive Impairment , 2006, Dementia and Geriatric Cognitive Disorders.

[84]  Kelvin H. Lee,et al.  Complement Protein Isoforms in CSF as Possible Biomarkers for Neurodegenerative Disease , 2005, Disease markers.

[85]  J. Price,et al.  Complement Activation in Very Early Alzheimer Disease , 2005, Alzheimer disease and associated disorders.

[86]  Jun Zhou,et al.  Absence of C1q Leads to Less Neuropathology in Transgenic Mouse Models of Alzheimer's Disease , 2004, The Journal of Neuroscience.

[87]  R. Strohmeyer,et al.  Association of factor H of the alternative pathway of complement with agrin and complement receptor 3 in the Alzheimer's disease brain , 2002, Journal of Neuroimmunology.

[88]  John D Lambris,et al.  Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[89]  Christos Davatzikos,et al.  Voxel-Based Morphometry Using the RAVENS Maps: Methods and Validation Using Simulated Longitudinal Atrophy , 2001, NeuroImage.

[90]  H. Sebastian Seung,et al.  Learning the parts of objects by non-negative matrix factorization , 1999, Nature.

[91]  T. Lehtimäki,et al.  Longitudinal stability of CSF tau levels in Alzheimer patients , 1999, Biological Psychiatry.

[92]  B. Bradt,et al.  Complement-dependent Proinflammatory Properties of the Alzheimer's Disease β-Peptide , 1998, The Journal of experimental medicine.

[93]  C. Cotman,et al.  beta-Amyloid activates complement by binding to a specific region of the collagen-like domain of the C1q A chain. , 1994, Journal of immunology.

[94]  P. Mcgeer,et al.  Complement activation by beta-amyloid in Alzheimer disease. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[95]  P. Eikelenboom,et al.  Complement activation in amyloid plaques in Alzheimer’s dementia , 1988, Virchows Archiv. B, Cell pathology including molecular pathology.

[96]  J. Ware,et al.  Random-effects models for longitudinal data. , 1982, Biometrics.

[97]  D. Perani,et al.  Cross-validation of biomarkers for the early differential diagnosis and prognosis of dementia in a clinical setting , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[98]  Stephen F. Carter,et al.  Concordance and Diagnostic Accuracy of [11C]PIB PET and Cerebrospinal Fluid Biomarkers in a Sample of Patients with Mild Cognitive Impairment and Alzheimer's Disease. , 2015, Journal of Alzheimer's disease : JAD.

[99]  F. Pasquier,et al.  Who needs cerebrospinal biomarkers? A national survey in clinical practice. , 2014, Journal of Alzheimer's disease : JAD.

[100]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[101]  F. Pasquier,et al.  Impact of cerebro-spinal fluid biomarkers of Alzheimer’s disease in clinical practice: a multicentric study , 2013, Journal of Neurology.

[102]  D. Selkoe.  Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[103]  P. Mcgeer,et al.  Neuroinflammation in Alzheimer's disease and mild cognitive impairment: a field in its infancy. , 2010, Journal of Alzheimer's disease : JAD.

[104]  Nick C Fox,et al.  Letter abstract - Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's Disease , 2009 .

[105]  C. Chiandetti,et al.  Conversion of mild cognitive impairment to dementia in elderly subjects: a preliminary study in a memory and cognitive disorder unit. , 2007, Archives of gerontology and geriatrics.

[106]  S. W. Nelson.  Department of Radiology , 1969 .